Presentation by James Thackeray, Chief Commercialization Officer, Lumea

Where Tissue Meets Tech: The Clinical Benefits and ROI in Digital Pathology Start Here

Share this article:

To derive real value from digital pathology the journey has to start at the time of the biopsy

Pre-analytical issues are central to specimen integrity and molecular quality. To derive real value from digital pathology the journey has to start at the beginning – at the time of the biopsy. James Thackeray presents a deep dive into prostate case studies demonstrating that when tissue handling technology precedes digital slides, there is an increase in the histologic tissue surface area, an increase in biopsy core lengths by 31.8%, and an increase in overall cancer detection rate by 9.3%. In addition to these significant tissue quality benefits, he will discuss the efficiency and cost savings realized in labs that adopt pre-analytic tissue tech.